U.S. markets open in 2 hours 20 minutes
  • S&P Futures

    3,771.25
    +5.75 (+0.15%)
     
  • Dow Futures

    30,937.00
    +59.00 (+0.19%)
     
  • Nasdaq Futures

    12,456.00
    +1.00 (+0.01%)
     
  • Russell 2000 Futures

    2,155.00
    +10.50 (+0.49%)
     
  • Crude Oil

    65.46
    +1.63 (+2.55%)
     
  • Gold

    1,692.70
    -8.00 (-0.47%)
     
  • Silver

    25.37
    -0.09 (-0.36%)
     
  • EUR/USD

    1.1939
    -0.0040 (-0.33%)
     
  • 10-Yr Bond

    1.5500
    0.0000 (0.00%)
     
  • Vix

    27.67
    +1.00 (+3.75%)
     
  • GBP/USD

    1.3821
    -0.0073 (-0.52%)
     
  • USD/JPY

    108.3690
    +0.3930 (+0.36%)
     
  • BTC-USD

    47,824.14
    -1,510.27 (-3.06%)
     
  • CMC Crypto 200

    956.30
    -30.91 (-3.13%)
     
  • FTSE 100

    6,679.49
    +28.61 (+0.43%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

iRobot Corporation (IRBT), Zendesk, Inc. (ZEN) & Zynerba Pharmaceuticals, Inc. (ZYNE)- Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Actions

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

NEW YORK, Dec. 13, 2019 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

iRobot Corporation (NASDAQ: IRBT)
Class Period: November 21, 2016 - October 22, 2019
Deadline: December 23, 2019
For more info: www.bgandg.com/irbt
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) iRobot’s explosive growth was not based on increased demand, expanding margins, and product innovations, as it claimed, but rather based on channel stuffing; (2) the Company attempted to conceal its actions by acquiring its distributors in Europe and Asia; (3) these acquisitions were designed to clean up the company’s global inventory and mask falling demand; and (4) as a result, iRobot’s public statements were materially false and misleading at all relevant times.

Zendesk, Inc. (NYSE: ZEN)
Class Period: February 6, 2019 - October 1, 2019
Deadline: December 23, 2019
For more info: www.bgandg.com/zen
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zendesk's clients had been subject to data breaches dating back to 2016; (2) Zendesk was experiencing slowing demand for its SaaS offerings, particularly in Germany, the U.K. and Australia, due in large part to political uncertainty and China trade issues; (3) for the forgoing reasons, Zendesk's business metrics and financial prospects were not as strong as represented during the Class Period; and (4) as a result, Zendesk's public statements were materially false and misleading at all relevant times.

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)
Class Period: March 11, 2019 - September 17, 2019
Deadline: December 23, 2019
For more info: www.bgandg.com/zyne
The Complaint alleges that, throughout the Class Period, defendants made false and/or misleading statements and/or failed to disclose that: (1) Zygel was proving unsafe and not well-tolerated in the BELIEVE 1 Trial; (2) the foregoing created a foreseeable, heightened risk that Zynerba would fail to secure the necessary regulatory approvals for commercializing Zygel for the treatment of DEE in children and adolescents; and (3) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com